TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19776507

Group type: EXPERIMENTAL
Intervention: 0.18% isotretinoin applied topically twice a day for one month
Number of subjects: 6

Group type: COMPARATOR
Intervention: Untreated control patients
Number of subjects: 6
Study: 17313376

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 2.1 microg/kg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 4.2 microg/kg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 6.3 microg/kg
Number of subjects: 93
Study: 15173298

Group type: EXPERIMENTAL
Intervention: anterior‐posterior‐glide Low Contact Stress mobile‐bearing prosthesis
Number of subjects: 190

Group type: COMPARATOR
Intervention: rotating‐platform Low Contact Stress mobile‐bearing prosthesis
Number of subjects: 190
Study: 11512369

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg.kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopental (5 mg.kg‐1)
Number of subjects: 60
Study: 9742659

Group type: EXPERIMENTAL
Intervention: 10 ppm D4 (122 micrograms/liter)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 12
Study: 7851104

Group type: EXPERIMENTAL
Intervention: Supported employment program (changed from day treatment)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Day treatment program (control)
Number of subjects: 183
Study: 3508329

Group type: EXPERIMENTAL
Intervention: 375 mg naproxen twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 750 mg naproxen twice daily
Number of subjects: 48
Study: 30592439

Group type: EXPERIMENTAL
Intervention: Assistive Home Technology (AHT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (without AHT)
Number of subjects: 54
Study: 29793566

Group type: EXPERIMENTAL
Intervention: Resin infiltration followed by five percent topical sodium fluoride (NaF) application
Number of subjects: 45

Group type: COMPARATOR
Intervention: Five percent sodium fluoride (NaF) alone
Number of subjects: 45
Study: 28007034

Group type: EXPERIMENTAL
Intervention: Internet-based intervention (tele-care support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study: 24630840

Group type: EXPERIMENTAL
Intervention: Tribulus terrestris 800 mg, divided into two doses per day for thirty days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo administered in the same way as the intervention
Number of subjects: 30
Study: 23782752

Group type: EXPERIMENTAL
Intervention: Trichuris suis ova 2,500 eggs every two weeks for 12 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 50
Study: 20409438

Group type: EXPERIMENTAL
Intervention: AA attendance
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Higher levels of anger
Number of subjects: 1706

Group type: COMPARATOR
Intervention: General population
Number of subjects: 1706
Study: 18956493

Group type: EXPERIMENTAL
Intervention: Naturopathy
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: Chiropractic
Number of subjects: 2527
Study: 16182024

Group type: EXPERIMENTAL
Intervention: Cervical spinal joint dysfunction at multiple sites
Number of subjects: 30
Study: 12207107

Group type: EXPERIMENTAL
Intervention: Treatment-resistant depression (TRD)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Non-treatment-resistant depression (non-TRD)
Number of subjects: 158
Study: 10408182

Group type: EXPERIMENTAL
Intervention: New sampling design based on individual information contribution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects sampled from risk sets or entire cohort
Number of subjects: 0
Study: 8727629

Group type: EXPERIMENTAL
Intervention: Directional-tip endotracheal tubes
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard endotracheal tubes
Number of subjects: 49
Study: 1773636

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Surgical Assessment
Number of subjects: 108
Study: 7053283

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone, 400 mg daily
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: S-warfarin with sulfinpyrazone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: R-warfarin with sulfinpyrazone
Number of subjects: 6
Study: 30074288

Group type: EXPERIMENTAL
Intervention: 1.5 T static magnetic field exposure
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3 T static magnetic field exposure
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0 T (placebo) static magnetic field exposure
Number of subjects: 18
Study: 27513640

Group type: EXPERIMENTAL
Intervention: Epidural 0.125% ropivacaine with dexmedetomidine (0.5 μg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural 0.125% ropivacaine
Number of subjects: 80
Study: 24923890

Group type: EXPERIMENTAL
Intervention: Face-to-face interview (FTFI)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Computer-assisted self-interview (CASI)
Number of subjects: 368
Study: 23531984

Group type: EXPERIMENTAL
Intervention: Internet-based photoaging intervention using APRIL Face Aging software
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standardized smoking cessation advice (Control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intervention group smoking dependence score
Number of subjects: 160
Study: 21336156

Group type: EXPERIMENTAL
Intervention: Quadruple sequential therapy plus 6 weeks of iron supplementation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Eradication therapy plus placebo
Number of subjects: 110

Group type: COMPARATOR
Intervention: Iron supplementation plus placebo
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 110
Study: 19839000

Group type: EXPERIMENTAL
Intervention: Green Tea Extracts (GTE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15998749

Group type: EXPERIMENTAL
Intervention: 40 g of isolated soybean protein supplements per day
Number of subjects: 302

Group type: COMPARATOR
Intervention: Complex carbohydrate control
Number of subjects: 302
Study: 12891107

Group type: EXPERIMENTAL
Intervention: SMCD (Suture-Mediated Closure Device)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Manual Compression
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SMCD
Number of subjects: 102

Group type: COMPARATOR
Intervention: SMCD and Manual Compression
Number of subjects: 102
Study: 10388246

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 166
Study: 8671813

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 1888640

Group type: EXPERIMENTAL
Intervention: NA 7CH (infinitesimal dilution of nalidixic acid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (succussed water)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AT 7CH (infinitesimal dilution of atenolol)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BI 7CH (infinitesimal dilution of bisoprolol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (for atenolol experiment)
Number of subjects: 20
Study: 6343154

Group type: EXPERIMENTAL
Intervention: Intravenous maprotiline (100 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous clomipramine (Anafranil)
Number of subjects: 40
Study: 31955859

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg once daily in a 28-day dosing cycle
Number of subjects: 133
Study: 31618331

Group type: EXPERIMENTAL
Intervention: BiPAP in post-anesthetic recovery (PAR) for one hour
Number of subjects: 40

Group type: COMPARATOR
Intervention: BiPAP on the first postoperative day (1PO) for one hour
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between PAR-G and 1PO-G
Number of subjects: 40
Study: 29457388

Group type: EXPERIMENTAL
Intervention: Extreme lateral interbody fusion (XLIF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional posterior operation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both XLIF and Conventional groups
Number of subjects: 60
Study: 24942382

Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks (Q2W)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks (Q4W)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 23937679

Group type: EXPERIMENTAL
Intervention: Epelsiban 50 mg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Epelsiban 150 mg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 20960341

Group type: EXPERIMENTAL
Intervention: 3-D ultrasound for complete tumour removal (group 1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 3-D ultrasound for incomplete tumour removal (group 2)
Number of subjects: 14
Study: 19782787

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP)
Number of subjects: 1383
Study: 17572830

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg, 1 hour before bedtime)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bright light (30‐minute exposure, individually scheduled)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 17012882

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV//PRP‐T combination vaccine (Pentacel) administered as a fourth dose at 15, 16, 17, or 18 months of age.
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV//PRP‐T combination vaccine (Pentacel) administered as a fourth dose.
Number of subjects: 1782
Study: 12459073

Group type: EXPERIMENTAL
Intervention: American Heart Association Step II diet for six months
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: pravastatin 10 mg
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: pravastatin 40 mg
Number of subjects: 191
Study: 10588407

Group type: EXPERIMENTAL
Intervention: ABT-418 (75 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9180791

Group type: EXPERIMENTAL
Intervention: Vitamin A (25,000 IU)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 1872308

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other sulfonylureas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6353838

Group type: EXPERIMENTAL
Intervention: 2% chloroprocaine
Number of subjects: 47

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 47
Study: 31125186

Group type: EXPERIMENTAL
Intervention: Hypertensive African Americans
Number of subjects: 2052
Study: 29578858

Group type: EXPERIMENTAL
Intervention: Water-based aerobic training (WA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study: 27573315

Group type: EXPERIMENTAL
Intervention: Social POD app (theory‐based podcasts + Social POD app)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard app (theory‐based podcasts + standard app)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Social POD app
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard app
Number of subjects: 51
Study: 24549101

Group type: EXPERIMENTAL
Intervention: RG3487 5 mg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: RG3487 50 mg
Number of subjects: 215

Group type: COMPARATOR
Intervention: RG3487 15 mg
Number of subjects: 215
Study: 22242614

Group type: EXPERIMENTAL
Intervention: Preoperative total parenteral nutrition (TPN) for 18‐90 days (mean, 46 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no preoperative TPN)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preoperative TPN
Number of subjects: 120
Study: 20575726

Group type: EXPERIMENTAL
Intervention: Telerehabilitation assessment by a remote therapist
Number of subjects: 19
Study: 17767002

Group type: EXPERIMENTAL
Intervention: ARC booklet and mind map together
Number of subjects: 363

Group type: COMPARATOR
Intervention: ARC booklet alone
Number of subjects: 363
Study: 16174587

Group type: EXPERIMENTAL
Intervention: Amino acid injection into the amniotic cavity
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous infusion of compound amino acid
Number of subjects: 44
Study: 12037731

Group type: EXPERIMENTAL
Intervention: 20 g of glucose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 g of mannitol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: acute exercise (80 J/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: insulin‐induced hypoglycemia
Number of subjects: 14
Study: 10221717

Group type: EXPERIMENTAL
Intervention: Relaxin administration (up to 10 times higher than during pregnancy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxin administration
Number of subjects: 0
Study: 8519717

Group type: EXPERIMENTAL
Intervention: Tightly wrapped legs with elastic bandages
Number of subjects: 24

Group type: COMPARATOR
Intervention: Loosely wrapped legs with elastic bandages (Control)
Number of subjects: 24
Study: 2354928

Group type: EXPERIMENTAL
Intervention: Interpretation of chest images with accompanying patient histories
Number of subjects: 247

Group type: COMPARATOR
Intervention: Interpretation of chest images without accompanying patient histories
Number of subjects: 247
Study: 345342

Group type: EXPERIMENTAL
Intervention: 0.25 mg glucagon
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.5 mg glucagon
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 mg glucagon
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29295829

Group type: EXPERIMENTAL
Intervention: Medication therapy management intervention (single home visit by a pharmacist within 7 days of discharge)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Medication therapy management intervention
Number of subjects: 141
Study: 27720040

Group type: EXPERIMENTAL
Intervention: DHA supplementation (high dose)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DHA supplementation (low dose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 23660572

Group type: EXPERIMENTAL
Intervention: Novel training program (NT)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Traditional Army physical training (TT)
Number of subjects: 133
Study: 23792178

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0
Study: 20739842

Group type: EXPERIMENTAL
Intervention: SLND alone
Number of subjects: 891

Group type: COMPARATOR
Intervention: SLND + ALND
Number of subjects: 891
Study: 18467618

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (ELA) of refluxing superficial axial veins using the CoolTouch CTEV 1320 nm laser and ultrasound-guided sclerotherapy of associated varicose veins with foamed sodium tetradecyl sulphate (STS).
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-operative cohort (control group).
Number of subjects: 35
Study: 15939027

Group type: EXPERIMENTAL
Intervention: Information entropy analysis with no assumption on data distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information entropy analysis assuming normal distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mutual information analysis
Number of subjects: 0
Study: 12826992

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 10403850

Group type: EXPERIMENTAL
Intervention: Neostigmine (2.0 mg intravenously)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (intravenous saline)
Number of subjects: 21
Study: 8899087

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 1000 mg plus vitamin D 250 IU (Oscal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1647337

Group type: EXPERIMENTAL
Intervention: Pyridostigmine, 30 mg three times daily for 10 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo, similar dosage and duration as treatment group
Number of subjects: 35
Study: 6344956

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 153
Study: 31335802

Group type: EXPERIMENTAL
Intervention: Oral tenofovir‐based pre‐exposure prophylaxis (PrEP)
Number of subjects: 0
Study: 30037068

Group type: EXPERIMENTAL
Intervention: Caloric Restriction (CR) 1000 cal/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Resveratrol (RSV) 500 mg/day
Number of subjects: 48
Study: 27372432

Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitor etoricoxib
Number of subjects: 16

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 16
Study: 23356505

Group type: EXPERIMENTAL
Intervention: Zinc sulphate/folic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinc sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23390784

Group type: EXPERIMENTAL
Intervention: Periarticular injection of 20 ml 0.25% bupivacaine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Isotonic saline solution (control)
Number of subjects: 99
Study: 20937112

Group type: EXPERIMENTAL
Intervention: PRIMUS Activities
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: PRIMUS QoL
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: U-FIS
Number of subjects: 911
Study: 18657677

Group type: EXPERIMENTAL
Intervention: ADD1 variant carriers (black patients)
Number of subjects: 5979

Group type: EXPERIMENTAL
Intervention: ADD1 variant carriers (Hispanic patients)
Number of subjects: 5979

Group type: EXPERIMENTAL
Intervention: ADD1 variant carriers (white patients)
Number of subjects: 5979

Group type: EXPERIMENTAL
Intervention: All-cause death (secondary outcome)
Number of subjects: 5979

Group type: COMPARATOR
Intervention: Diuretic use
Number of subjects: 5979
Study: 15915026

Group type: EXPERIMENTAL
Intervention: Active nicotine-containing patches
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 121
Study: 12679359

Group type: EXPERIMENTAL
Intervention: Maximal exercise (graded upright cycle ergometry to volitional exhaustion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 8
Study: 10954343

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9252901

Group type: EXPERIMENTAL
Intervention: 13C-xylose (50 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control groups (10 mg and 25 mg 13C-xylose)
Number of subjects: 35
Study: 8391042

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (administered in a step-down schedule for 12 months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon
Number of subjects: 72
Study: 3505532

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg oral administration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29335043

Group type: EXPERIMENTAL
Intervention: Endoscopic repair using a mirrored L‐shaped flap without stenting (Group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Endoscopic repair using stenting without a flap (Group B)
Number of subjects: 72
Study: 28410809

Group type: EXPERIMENTAL
Intervention: Radiotherapy 60Gy/30 fractions with oral vinorelbine 50mg 3 times weekly
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Radiotherapy 66Gy/33 fractions with oral vinorelbine 50mg 3 times weekly
Number of subjects: 117
Study: 26154736

Group type: EXPERIMENTAL
Intervention: Posterior subtenon's injection of 40 mg of triamcinolone acetonide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Grid laser photocoagulation (GLP) combined with posterior subtenon's triamcinolone injection
Number of subjects: 42
Study: 23496861

Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarettes (16 mg)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Placebo e-cigarettes (no nicotine)
Number of subjects: 657
Study: 21680726

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control therapy (IT) for 2 weeks
Number of subjects: 48
Study: 17519926

Group type: EXPERIMENTAL
Intervention: Intake of vitamin C-rich vegetables (bell peppers and broccoli)
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Fruit and other vegetables
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Vitamin A intakes
Number of subjects: 1985
Study: 16410147

Group type: EXPERIMENTAL
Intervention: PNP care
Number of subjects: 76

Group type: COMPARATOR
Intervention: RES care
Number of subjects: 76
Study: 15012688

Group type: EXPERIMENTAL
Intervention: Low GDP solution (pH 7.0)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High GDP solution (pH 5.5)
Number of subjects: 26
Study: 10897510

Group type: EXPERIMENTAL
Intervention: Counselling (70 patients)
Number of subjects: 136

Group type: COMPARATOR
Intervention: GP care (66 patients)
Number of subjects: 136
Study: 9085977

Group type: EXPERIMENTAL
Intervention: BIS-guided group (anesthetic drug doses increased to produce a lower BIS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (BIS recorded, no action taken)
Number of subjects: 300
Study: 8441793

Group type: EXPERIMENTAL
Intervention: SAMe 1,600 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31980861

Group type: EXPERIMENTAL
Intervention: Anatomically contoured fibular plates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramedullary nail fixation
Number of subjects: 0
Study: 31080092

Group type: EXPERIMENTAL
Intervention: Telephone peer coaching (weekly 30-min calls for 6 months)
Number of subjects: 115
Study: 27973335

Group type: EXPERIMENTAL
Intervention: Non-invasive coronary multislice computed tomography angiography (MSCT) assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive conventional angiography assessment
Number of subjects: 0